Drug Makers To Congress: Reject Accelerated Approval Pay Reforms

By Gabrielle Wanneh / August 2, 2021 at 3:50 PM

Drug makers researching rare disease treatments are urging congressional health committees to reject calls by Medicaid payment advisers to update reimbursement policies for drugs granted accelerated approval by FDA.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.